#Japan #diabetes management #Shibuya #FreeStyle Libre #THE PHAGE

THE PHAGE and Abbott's FreeStyle Libre: A Revolutionary Step in Diabetes Management

On May 7, 2025, THE PHAGE, a pioneering digital health startup based in Shibuya, Tokyo, announced a groundbreaking integration with Abbott's FreeStyle Libre, a continuous glucose monitoring (CGM) device. This integration marks the first instance of API collaboration between a Japanese company and Abbott, enhancing diabetes management support through their innovative app, Glucose Flight®.

The Significance of API Integration

This collaboration aims to amalgamate real-time glucose data from FreeStyle Libre into THE PHAGE's Glucose Flight® app, which helps users predict postprandial blood sugar levels and offers data-driven health guidance. With over 7 million users across 60 countries, Abbott's FreeStyle Libre is renowned for its cutting-edge glucose measurement technology, making this partnership particularly notable.

Historically, only global medical device manufacturers and diabetes management apps have achieved API integrations with Abbott’s systems. This venture by THE PHAGE not only enhances the user experience but also accelerates the evolution of digital health solutions tailored for patients with diabetes in Japan.

Enhancements Through Official API Integration

The newly established API connection enriches various functionalities within the Glucose Flight® application, providing:

• - Integrated Management of Blood Sugar Trends: Track and record meals, exercise, and lifestyle habits in real time.
• - Automatic Reflection of Glucose Data: Glucose measurements from FreeStyle Libre are instantly updated in the app for convenience.
• - Comprehensive Health Management: Users can merge food, exercise, and lifestyle records to facilitate holistic health monitoring.
• - Personalized Blood Sugar Predictions Powered by AI: AI analyzes CGM data to predict individual patterns in blood sugar variation based on meals and physical activities.
• - Advanced Diabetes Risk Management: The app detects significant fluctuations in blood sugar trends at specified critical points.

Future Developments

The PHAGE intends to leverage this API integration to introduce diverse solutions in the diabetes management market, including remote nutritional guidance and blood glucose data analysis services for food CROs under medical supervision. The company is committed to collaborating with healthcare providers, corporations, and research institutions to establish a data-driven platform aimed at preventing severe diabetes complications.

About THE PHAGE

Founded on July 15, 2021, THE PHAGE is driven by its mission to create a society based on biological needs. This startup excels in providing digital health services centered around diabetes management, utilizing AI for blood sugar prediction and analysis to deliver personalized health management solutions tailored to individual lifestyles.

About Abbott

Abbott, a global healthcare leader, strives to empower people to live their best lives across all stages. Known for pioneering diagnostic devices, medical equipment, nutritional products, and branded generic medications, Abbott's innovative technologies leave a profound impact on healthcare across various domains, employing approximately 114,000 individuals in over 160 countries.

Contact Information

For media inquiries related to this release, please contact:
Public Relations: [email protected]

This partnership between THE PHAGE and Abbott promises an exciting future for diabetes management, ushering in new possibilities through technology and innovation.